Cartilage lesion treatments require expanding cells from healthy donor cartilage which have limited availability and restricted potential to produce cartilage. This invention overcomes these challenges, presenting chemical and physical methods for enhancing cell populations capable of producing neocartilage. According to a 2015 global market report, tissue engineering technologies are expected to reach over 94B USD by 2022.
The invention features improved cell expansion and cell culturing methods for enhancing cell populations capable of producing neocartilage. UCI scientists discovered that introducing specific chemical and cellular agents during the cell isolation process and culturing the cells in 3-D yielded neocartilage implants with significantly more mechanical robustness compared to those not treated with the same parameters. Notably, the invention enables a large quantity of engineered cartilage implants to be produced from few cells. They have demonstrated with only a few cells, 1.5M cells can be generated and fully capable of synthesizing cartilage with functional properties similar to native cartilage. More specifically, if 133 primary cells (0.01mm3 biopsy) is needed to completely resurface an adult knee, the invention would enable neocartilage production from a biopsy the size of 1mm3 (1 uL) to yield enough cells to completely resurface cover 75 knees.
|United States Of America||Published Application||20190085292||03/21/2019||2017-965|
Additional Patent Pending
In vitro evaluation of native and engineered tissues using cadaveric articular cartilage Assessed biomechanical and biochemical properties